RxDoctor Payments Data

Mei He, MD

Neurology · Dakota Dunes, SDNPI 1790982395

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,257 of the $4,697 with a category attached, or 69.3%. Inspire Medical Systems, Inc. accounts for 62.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $3,014 and has fallen 71.1% since, to $870 in 2025.

$4,697in general payments, 2019–2025

Across 114 payments — averaging $41.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$3K
  • AbbVie$556
  • Itamar Medical Inc$322
  • Teva Pharmaceuticals USA, Inc.$125
  • SK Life Science, Inc.$123
  • Abbott$93
  • plus $523 from 13 others

What the payments were for

  • Travel & lodging$1,44031%
  • Food & beverage$3,25769%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,697 in reported general payments places this provider in the 80th percentile of 49 neurology providers in South Dakota.

See all neurology providers in South Dakota

Medicare billing

Part B allowed, 2024
$468,890
Medicare patients
610
Services billed
49,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina22$34,509
BriviactBrivaracetam19$27,111
ZonegranZonisamide14$26,648
Levetiracetam113$2,591
Carbidopa-LevodopaCarbidopa/Levodopa59$1,741
Divalproex Sodium36$898
Gabapentin67$837
Clorazepate Dipotassium12$679
Propranolol Hcl ErPropranolol Hcl24$560
Baclofen35$483
Levetiracetam ErLevetiracetam16$451
Topiramate62$313
Carbidopa-Levodopa ErCarbidopa/Levodopa13$306
Donepezil Hcl37$299
Lamotrigine20$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$556$34,50922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 neurology providers in South Dakota.

Other neurology in Dakota Dunes

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →